Jeffrey Wiezorek
Founder presso Appia Bio, Inc.
Posizioni attive di Jeffrey Wiezorek
Società | Posizione | Inizio | Fine |
---|---|---|---|
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Director/Board Member | 01/01/2020 | - |
Chief Tech/Sci/R&D Officer | 01/01/2020 | - | |
Founder | 01/01/2020 | - |
Storia della carriera di Jeffrey Wiezorek
Precedenti posizioni note di Jeffrey Wiezorek
Società | Posizione | Inizio | Fine |
---|---|---|---|
AMGEN INC. | Corporate Officer/Principal | 01/10/2009 | 01/04/2014 |
KITE PHARMA INC | Chief Tech/Sci/R&D Officer | 12/05/2014 | - |
Corporate Officer/Principal | 12/05/2014 | - |
Formazione di Jeffrey Wiezorek
The Trustees of Columbia University in The City of New York | Doctorate Degree |
University of Pennsylvania | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
AMGEN INC. | Health Technology |
Aziende private | 2 |
---|---|
Kite Pharma, Inc.
Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Health Technology |
- Borsa valori
- Insiders
- Jeffrey Wiezorek
- Esperienza